BIOMAT Database Logo BIOMAT Database Logo

The base component of 3'-azido-2',3'-dideoxynucleosides influences resistance mutations selected in HIV-1 reverse transcriptase. 2011

Jeffrey D Meteer, and Dianna Koontz, and Ghazia Asif, and Hong-wang Zhang, and Mervi Detorio, and Sarah Solomon, and Steven J Coats, and Nicolas Sluis-Cremer, and Raymond F Schinazi, and John W Mellors
University of Pittsburgh School of Medicine, Department of Medicine, Division of Infectious Diseases, Pittsburgh, PA 15261, USA.

We recently reported that HIV-1 resistant to 3'-azido-3'-deoxythymidine (AZT) is not cross-resistant to 3'-azido-2',3'-dideoxypurines. This finding suggested that the nucleoside base is a major determinant of HIV-1 resistance to nucleoside analogs. To further explore this hypothesis, we conducted in vitro selection experiments by serial passage of HIV-1(LAI) in MT-2 cells in increasing concentrations of 3'-azido-2',3'-dideoxyguanosine (3'-azido-ddG), 3'-azido-2',3'-dideoxycytidine (3'-azido-ddC), or 3'-azido-2',3'-dideoxyadenosine (3'-azido-ddA). 3'-Azido-ddG selected for virus that was 5.3-fold resistant to 3'-azido-ddG compared to wild-type HIV-1(LAI) passaged in the absence of drug. Population sequencing of the entire reverse transcriptase (RT) gene identified L74V, F77L, and L214F mutations in the polymerase domain and K476N and V518I mutations in the RNase H domain. However, when introduced into HIV-1 by site-directed mutagenesis, these 5 mutations only conferred ∼2.0-fold resistance. Single-genome sequencing analyses of the selected virus revealed a complex population of mutants that all contained L74V and L214F linked to other mutations, including ones not identified during population sequencing. Recombinant HIV-1 clones containing RT derived from single sequences exhibited 3.2- to 4.0-fold 3'-azido-ddG resistance. In contrast to 3'-azido-ddG, 3'-azido-ddC selected for the V75I mutation in HIV-1 RT that conferred 5.9-fold resistance, compared to the wild-type virus. Interestingly, we were unable to select HIV-1 that was resistant to 3'-azido-ddA, even at concentrations of 3'-azido-ddA that yielded high intracellular levels of 3'-azido-ddA-5'-triphosphate. Taken together, these findings show that the nucleoside base is a major determinant of HIV-1 resistance mechanisms that can be exploited in the design of novel nucleoside RT inhibitors.

UI MeSH Term Description Entries
D001386 Azides Organic or inorganic compounds that contain the -N3 group. Azide
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015224 Dideoxynucleosides Nucleosides that have two hydroxy groups removed from the sugar moiety. The majority of these compounds have broad-spectrum antiretroviral activity due to their action as antimetabolites. The nucleosides are phosphorylated intracellularly to their 5'-triphosphates and act as chain-terminating inhibitors of viral reverse transcription. 2',3'-Dideoxynucleosides,Dideoxyribonucleosides,ddNus,2',3' Dideoxynucleosides
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D016047 Zalcitabine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. 2',3'-Dideoxycytidine,Dideoxycytidine,ddC (Antiviral),HIVID Roche,Hivid,NSC-606170,2',3' Dideoxycytidine,NSC 606170,NSC606170
D016048 Dideoxyadenosine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite. 2',3'-Dideoxyadenosine,ddA (Antiviral),2',3' Dideoxyadenosine
D016297 Mutagenesis, Site-Directed Genetically engineered MUTAGENESIS at a specific site in the DNA molecule that introduces a base substitution, or an insertion or deletion. Mutagenesis, Oligonucleotide-Directed,Mutagenesis, Site-Specific,Oligonucleotide-Directed Mutagenesis,Site-Directed Mutagenesis,Site-Specific Mutagenesis,Mutageneses, Oligonucleotide-Directed,Mutageneses, Site-Directed,Mutageneses, Site-Specific,Mutagenesis, Oligonucleotide Directed,Mutagenesis, Site Directed,Mutagenesis, Site Specific,Oligonucleotide Directed Mutagenesis,Oligonucleotide-Directed Mutageneses,Site Directed Mutagenesis,Site Specific Mutagenesis,Site-Directed Mutageneses,Site-Specific Mutageneses
D017423 Sequence Analysis, RNA A multistage process that includes cloning, physical mapping, subcloning, sequencing, and information analysis of an RNA SEQUENCE. RNA Sequence Analysis,Sequence Determination, RNA,Analysis, RNA Sequence,Determination, RNA Sequence,Determinations, RNA Sequence,RNA Sequence Determination,RNA Sequence Determinations,RNA Sequencing,Sequence Determinations, RNA,Analyses, RNA Sequence,RNA Sequence Analyses,Sequence Analyses, RNA,Sequencing, RNA
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse

Related Publications

Jeffrey D Meteer, and Dianna Koontz, and Ghazia Asif, and Hong-wang Zhang, and Mervi Detorio, and Sarah Solomon, and Steven J Coats, and Nicolas Sluis-Cremer, and Raymond F Schinazi, and John W Mellors
Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance.
January 2007, Proceedings of the National Academy of Sciences of the United States of America,
Jeffrey D Meteer, and Dianna Koontz, and Ghazia Asif, and Hong-wang Zhang, and Mervi Detorio, and Sarah Solomon, and Steven J Coats, and Nicolas Sluis-Cremer, and Raymond F Schinazi, and John W Mellors
3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes.
August 1998, Proceedings of the National Academy of Sciences of the United States of America,
Jeffrey D Meteer, and Dianna Koontz, and Ghazia Asif, and Hong-wang Zhang, and Mervi Detorio, and Sarah Solomon, and Steven J Coats, and Nicolas Sluis-Cremer, and Raymond F Schinazi, and John W Mellors
Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase.
March 2000, The Journal of biological chemistry,
Jeffrey D Meteer, and Dianna Koontz, and Ghazia Asif, and Hong-wang Zhang, and Mervi Detorio, and Sarah Solomon, and Steven J Coats, and Nicolas Sluis-Cremer, and Raymond F Schinazi, and John W Mellors
Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine.
July 2003, AIDS (London, England),
Jeffrey D Meteer, and Dianna Koontz, and Ghazia Asif, and Hong-wang Zhang, and Mervi Detorio, and Sarah Solomon, and Steven J Coats, and Nicolas Sluis-Cremer, and Raymond F Schinazi, and John W Mellors
Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency.
November 2008, AIDS (London, England),
Jeffrey D Meteer, and Dianna Koontz, and Ghazia Asif, and Hong-wang Zhang, and Mervi Detorio, and Sarah Solomon, and Steven J Coats, and Nicolas Sluis-Cremer, and Raymond F Schinazi, and John W Mellors
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.
January 2007, AIDS (London, England),
Jeffrey D Meteer, and Dianna Koontz, and Ghazia Asif, and Hong-wang Zhang, and Mervi Detorio, and Sarah Solomon, and Steven J Coats, and Nicolas Sluis-Cremer, and Raymond F Schinazi, and John W Mellors
Substrate mimicry: HIV-1 reverse transcriptase recognizes 6-modified-3'-azido-2',3'-dideoxyguanosine-5'-triphosphates as adenosine analogs.
January 2012, Nucleic acids research,
Jeffrey D Meteer, and Dianna Koontz, and Ghazia Asif, and Hong-wang Zhang, and Mervi Detorio, and Sarah Solomon, and Steven J Coats, and Nicolas Sluis-Cremer, and Raymond F Schinazi, and John W Mellors
APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations.
September 2004, AIDS (London, England),
Jeffrey D Meteer, and Dianna Koontz, and Ghazia Asif, and Hong-wang Zhang, and Mervi Detorio, and Sarah Solomon, and Steven J Coats, and Nicolas Sluis-Cremer, and Raymond F Schinazi, and John W Mellors
Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms.
August 2008, The Journal of biological chemistry,
Jeffrey D Meteer, and Dianna Koontz, and Ghazia Asif, and Hong-wang Zhang, and Mervi Detorio, and Sarah Solomon, and Steven J Coats, and Nicolas Sluis-Cremer, and Raymond F Schinazi, and John W Mellors
3'-Azido-3',5'-dideoxythymidine-5'-methylphosphonic acid diphosphate: synthesis and HIV-1 reverse transcriptase inhibition.
August 1992, Journal of medicinal chemistry,
Copied contents to your clipboard!